Comment
doi: 10.1016/S0140-6736(11)61298-1.
Cardiac myosin activation: will theory and practice coincide?
Affiliations
- PMID: 21856465
- DOI: 10.1016/S0140-6736(11)61298-1
Item in Clipboard
Comment
Cardiac myosin activation: will theory and practice coincide?
Lancet.
.
No abstract available
Comment on
-
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.Lancet. 2011 Aug 20;378(9792):667-75. doi: 10.1016/S0140-6736(11)61219-1. Lancet. 2011. PMID: 21856480 Clinical Trial.
-
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4. Lancet. 2011. PMID: 21856481 Clinical Trial.
Similar articles
-
Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.Eur J Med Chem. 2017 Jul 7;134:379-391. doi: 10.1016/j.ejmech.2017.04.005. Epub 2017 Apr 7. Eur J Med Chem. 2017. PMID: 28432943
-
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.Expert Opin Investig Drugs. 2016;25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19. Expert Opin Investig Drugs. 2016. PMID: 26587768 Review.
-
Medicine. Chemically tuned myosin motors.Science. 2011 Mar 18;331(6023):1392-3. doi: 10.1126/science.1204207. Science. 2011. PMID: 21415340 No abstract available.
-
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4. Lancet. 2011. PMID: 21856481 Clinical Trial.
-
A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF.Cardiol Rev. 2013 May-Jun;21(3):155-9. doi: 10.1097/CRD.0b013e318275889c. Cardiol Rev. 2013. PMID: 23018669 Review.
Cited by
-
Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.J Cardiovasc Pharmacol. 2014 Sep;64(3):199-208. doi: 10.1097/FJC.0000000000000113. J Cardiovasc Pharmacol. 2014. PMID: 24785346 Free PMC article. Review.
-
Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.Circ Res. 2013 May 10;112(10):1334-44. doi: 10.1161/CIRCRESAHA.113.301055. Epub 2013 Mar 26. Circ Res. 2013. PMID: 23532597 Free PMC article.
-
New perspective in heart failure management: could myosin activators be the answer?Discoveries (Craiova). 2014 Dec 31;2(4):e33. doi: 10.15190/d.2014.25. Discoveries (Craiova). 2014. PMID: 32309560 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
